Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29896445 | 0.86 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL30153455 | 0.81 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL5428722 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL3548138 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5415967 | 0.78 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL9326944 | 0.78 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADORA3ALDH1A1 | |
| SCHEMBL9427973 | 0.77 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL23447725 | 0.75 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADORA3KDM4E | |
| SCHEMBL9325861 | 0.75 | ADORA3 (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL9264847 | 0.75 | ADORA3 (1.00) | ADORA2AADORA1ADORA2BADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | claimed |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | claimed |
| EP-1633756-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004092173-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | disclosed |
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-114728998-A | Sulfonamide compounds targeting CD73 and adenosine receptors | 奥瑞基尼探索技术有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-7834014-B2 | Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol; | BIOGEN IDEC MA INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7285550-B2 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070173505-A1 | A2a adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2007-07-26 | — | — | US | disclosed |
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173505-A1 | A2a adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885 |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | ADORA2A, ADORA2B, ENTPD5 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.